Gliomas are the most common central nervous tumors in children and adolescents. However, spinal cord low-grade gliomas (sLGGs) are rare, with scarce information on tumor genomics and epigenomics. To define the molecular landscape of sLGGs, we integrated clinical data, histology, and multi-level genetic and epigenetic analyses on a consecutive cohort of 26 pediatric patients. Driver molecular alteration was found in 92% of patients (24/26). A novel variant of KIAA1549:BRAF fusion (ex10:ex9) was identified using RNA-seq in four cases. Importantly, only one-third of oncogenic drivers could be revealed using standard diagnostic methods, and two-thirds of pediatric patients with sLGGs required extensive molecular examination. The majority (23/24) of detected alterations were potentially druggable targets. Four patients in our cohort received targeted therapy with MEK or NTRK inhibitors. Three of those exhibited clinical improvement (two with trametinib, one with larotrectinib), and two patients achieved partial response. Methylation profiling was implemented to further refine the diagnosis and revealed intertumoral heterogeneity in sLGGs. Although 55% of tumors clustered with pilocytic astrocytoma, other rare entities were identified in this patient population. In particular, diffuse leptomeningeal glioneuronal tumors (n = 3) and high-grade astrocytoma with piloid features (n = 1) and pleomorphic xanthoastrocytoma (n = 1) were present. A proportion of tumors (14%) had no match with the current version of the classifier. Complex molecular genetic sLGGs characterization was invaluable to refine diagnosis, which has proven to be essential in such a rare tumor entity. Moreover, identifying a high proportion of drugable targets in sLGGs opened an opportunity for new treatment modalities.

Department of Neurology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Neurosurgery 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University Prague and Faculty Hospital Motol Prague Czech Republic

Department of Pediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Pediatric Oncology and Hematology Children's University Hospital Banska Bystrica Slovakia

Department of Radiology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Division of Biostatistics German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Heidelberg Germany

Pediatric Glioma Research Group German Cancer Research Center Heidelberg Germany

Prague Brain Tumor Research Group 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Acta Neuropathol Commun. 2022 Nov 11;10(1):162. doi: 10.1186/s40478-022-01467-9. PubMed

Zobrazit více v PubMed

Barker DJP, Weller RO, Garfield JS. Epidemiology of primary tumours of the brain and spinal cord: a regional survey in southern England. J Neurol Neurosurg Psychiatry. 1976;39:290–296. doi: 10.1136/jnnp.39.3.290. PubMed DOI PMC

Constantini S, Miller DC, Allen JC, Rorke LB, Freed D, Epstein FJ. Radical excision of intramedullary spinal cord tumors: surgical morbidity and long-term follow-up evaluation in 164 children and young adults. J Neurosurg Spine. 2000;93:183–193. doi: 10.3171/spi.2000.93.2.0183. PubMed DOI

Gnekow AK, Kandels D, Van TC, Azizi AA, Opocher E, Stokland T, et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;231:107–135. doi: 10.1055/a-0889-8256. PubMed DOI

Beneš V, Barsa P, Beneš V, Suchomel P. Prognostic factors in intramedullary astrocytomas: a literature review. Eur Spine J. 2009;18:1397–1422. doi: 10.1007/s00586-009-1076-8. PubMed DOI PMC

Grob ST, Nobre L, Campbell KR, Davies KD, Ryall S, Aisner DL, et al. Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. Neuro-Oncol Adv. 2020;2:1–9. PubMed PMC

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30:1323–1341. doi: 10.1016/j.mri.2012.05.001. PubMed DOI PMC

Tian Y, Rich BE, Vena N, Craig JM, MacConaill LE, Rajaram V, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011;13:669–677. doi: 10.1016/j.jmoldx.2011.07.002. PubMed DOI PMC

Uhrig S, Ellermann J, Walther T, Burkhardt P, Frohlich M, Hutter B, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31:448–460. doi: 10.1101/gr.257246.119. PubMed DOI PMC

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474. doi: 10.1038/nature26000. PubMed DOI PMC

Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019;25:1422–1427. doi: 10.1038/s41591-019-0542-z. PubMed DOI PMC

Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673–8677. doi: 10.1158/0008-5472.CAN-08-2097. PubMed DOI PMC

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N, et al. A systematicBRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739–1749. doi: 10.1172/JCI33656. PubMed DOI PMC

Konar SK, Bir SC, Maiti TK, Nanda A. A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord. J Neurosurg Pediatr. 2017;19:239–248. doi: 10.3171/2016.8.PEDS1631. PubMed DOI

Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1000 pediatric low-grade gliomas. Cancer Cell. 2020;37:569–583.e5. doi: 10.1016/j.ccell.2020.03.011. PubMed DOI PMC

Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:2641–2647. doi: 10.1200/JCO.2011.36.6054. PubMed DOI PMC

Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report. Eur J Cancer. 2017;81:206–225. doi: 10.1016/j.ejca.2017.04.019. PubMed DOI PMC

Clarke M, Mackay A, Ismer B, Pickles JC, Tatevossian RG, Newman S, et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov. 2020;10:942–963. doi: 10.1158/2159-8290.CD-19-1030. PubMed DOI PMC

Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun. 2019;10:1–13. doi: 10.1038/s41467-019-12187-5. PubMed DOI PMC

Chiang JCH, Harreld JH, Orr BA, Sharma S, Ismail A, Segura AD, et al. Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination. Acta Neuropathol. 2017;134:159–162. doi: 10.1007/s00401-017-1728-4. PubMed DOI PMC

Daoud EV, Wachsmann M, Richardson TE, Mella D, Pan E, Schwarzbach A, et al. Spinal pleomorphic xanthoastrocytoma with a QKI-RAF1 fusion. J Neuropathol Exp Neurol. 2019;78:10–14. doi: 10.1093/jnen/nly112. PubMed DOI

Chai RC, Zhang YW, Liu YQ, Chang YZ, Pang B, Jiang T, et al. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun. 2020;8:1–11. doi: 10.1186/s40478-020-00913-w. PubMed DOI PMC

Zhang M, Iyer RR, Azad TD, Wang Q, Garzon-Muvdi T, Wang J, et al. Genomic landscape of intramedullary spinal cord gliomas. Sci Rep. 2019;9:1–8. PubMed PMC

Lebrun L, Bizet M, Melendez B, Alexiou B, Absil L, Van Campenhout C, et al. Analyses of DNA methylation profiling in the diagnosis of intramedullary astrocytomas. J Neuropathol Exp Neurol. 2021;80:663–673. PubMed PMC

Biczok A, Strübing FL, Eder JM, Egensperger R, Schnell O, Zausinger S, et al. Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas. Acta Neuropathol Commun. 2021;9:119. doi: 10.1186/s40478-021-01222-6. PubMed DOI PMC

Selt F, Van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020;149:499–510. doi: 10.1007/s11060-020-03640-3. PubMed DOI PMC

Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, et al. Trametinib for progressive pediatric low-grade gliomas. J Neurooncol. 2018;140:435–444. doi: 10.1007/s11060-018-2971-9. PubMed DOI

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–739. doi: 10.1056/NEJMoa1714448. PubMed DOI PMC

D’Arco F, O’Hare P, Dashti F, Lassaletta A, Loka T, Tabori U, et al. Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. Neuroradiology. 2018;60:427–436. doi: 10.1007/s00234-018-1979-3. PubMed DOI

Fangusaro J, Witt O, Hernáiz Driever P, Bag AK, de Blank P, Kadom N, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21:e305–e316. doi: 10.1016/S1470-2045(20)30064-4. PubMed DOI

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions

Correction to: Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas